NCT05527418View on ClinicalTrials.gov

Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection

PHASE2RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

January 26, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Recent HIV-1 Infection

Interventions

DRUG

Dasatinib

Dasatinib monotherapy 70 mg/day, during 16 weeks.

DRUG

Placebo

Placebo during 16 weeks.

Trial Locations (1)

Unknown

RECRUITING

Eva Bonfill, Barcelona

All Listed Sponsors

lead

Eva Bonfill

OTHER